165 related articles for article (PubMed ID: 32464187)
1. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM
J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo.
Blanton RM; Takimoto E; Lane AM; Aronovitz M; Piotrowski R; Karas RH; Kass DA; Mendelsohn ME
J Am Heart Assoc; 2012 Oct; 1(5):e003731. PubMed ID: 23316302
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
[TBL] [Abstract][Full Text] [Related]
8. A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload.
Maslov MY; Foianini S; Orlov MV; Januzzi JL; Lovich MA
J Card Fail; 2018 Nov; 24(11):773-782. PubMed ID: 30347271
[TBL] [Abstract][Full Text] [Related]
9. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
10. CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure.
Richards DA; Aronovitz MJ; Liu P; Martin GL; Tam K; Pande S; Karas RH; Bloomfield DM; Mendelsohn ME; Blanton RM
Circ Heart Fail; 2021 Jan; 14(1):e007300. PubMed ID: 33464954
[TBL] [Abstract][Full Text] [Related]
11. Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate.
Thoonen R; Giovanni S; Govindan S; Lee DI; Wang GR; Calamaras TD; Takimoto E; Kass DA; Sadayappan S; Blanton RM
Circ Heart Fail; 2015 Nov; 8(6):1115-22. PubMed ID: 26477830
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
15. PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension.
Ramchandran R; Raghavan A; Geenen D; Sun M; Bach L; Yang Q; Raj JU
Am J Physiol Lung Cell Mol Physiol; 2014 Oct; 307(7):L537-44. PubMed ID: 25128522
[TBL] [Abstract][Full Text] [Related]
16. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
17. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
[TBL] [Abstract][Full Text] [Related]
19. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
